Sector News

Sprout CEO Whitehead departs Valeant

December 11, 2015
Life sciences

In August, female libido drug maker Sprout agreed to a $1 billion buyout from Valeant that would make it a division of the Canadian pharma run by its current CEO, Cindy Whitehead. Now, though–less than four months later–Whitehead is on her way out.

As Valeant spokeswoman Laurie Little told The New York Times in a statement, the drugmaker and Whitehead “mutually agreed that it was the right time to transition to new leadership for the next phase of global commercialization” after assembling a team to take Sprout’s “female Viagra”–Addyi–to market.

“Thanks to the efforts of Cindy and her team, Valeant has the opportunity to make Addyi broadly available to patients in need of this important medical treatment,” Little said.

Those efforts include winning FDA approval for the treatment, which Boehringer Ingelheim had dropped and the FDA had twice rejected before the agency finally green-lighted Addyi this summer. And striking the pact with Valeant–which Sprout did just one day after winning the regulatory go-ahead–helped lay the foundation for the drug’s commercial push.

But so far, the launch hasn’t exactly gone the way Sprout and Valeant expected. Between Oct. 17 and Nov. 6, total Addyi scripts had only tallied 227–a far cry from the half a million scripts Pfizer’s Viagra posted in its first month after launch.

Of course, there are major differences between the two drugs that make them difficult to fairly compare. Addyi registered marginal efficacy over placebo in trials, and it doesn’t provide the immediately obvious effects that Viagra and its fellow ED treatments can. On top of that, the risk of serious side effects netted the med the FDA’s black-box safety warning, and doctors must be certified to prescribe it.

Still, though, it’s an apparent lack of interest from women that has surprised some industry watchers, especially in the wake of the intense lobbying effort–and media attention–around its approval.

“I thought there was going to be this huge onslaught,” Stephanie Faubion, director of the Women’s Health Clinic at the Mayo Clinic, recently told Bloomberg. “There have been a few casual inquiries, but no prescriptions yet.”

Meanwhile, Whitehead’s departure is “also incrementally negative as it could indicate that Valeant is losing some of its senior managers following the recent decline in its stock price,” BMO Capital Markets analyst Alex Arfaei told Bloomberg. Shares of the Quebec-based drugmaker have been hit hard on recent government pricing probes and allegations that it used its specialty pharmacy relationships to inflate its top line.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach